PAIGE WEAVER: Open Payments
NPI 1821668039 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,805 in 106 payments from 21 companies in 2025. Trend: 2023 $495 · 2024 $1,752 · 2025 $1,805
Food & beverage: $1,805
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 19 | $287 |
| Novo Nordisk Inc | 19 | $272 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $215 |
| ABBVIE INC. | 14 | $195 |
| AstraZeneca Pharmaceuticals LP | 4 | $162 |
| GlaxoSmithKline, LLC. | 4 | $97 |
| PFIZER INC. | 5 | $82 |
| Dexcom, Inc. | 4 | $71 |
| Astellas Pharma US Inc | 3 | $62 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $57 |
Products named: JARDIANCE, MOUNJARO, Ozempic, FARXIGA, Rybelsus, TRELEGY ELLIPTA, Dexcom G6 Transmitter, QULIPTA.
Industry payments across TX — which companies pay providers there.
